Abstract
In recent years, there has been an increasing interest in endovascular iliofemoral vein stenting to prevent/ alleviate symptoms related to proximal venous outflow obstruction. Maintaining long-term stent patency is one of the main challenges, and risk factors for the development of re-thrombosis are not well understood. Published data on the safety and efficacy of the procedure predominantly come from cohort studies mainly focusing on mechanical aspects relating to stent placement and flow. Aetiology of thrombus formation and thrombotic tendencies of patients due to underlying medical conditions are not captured well or linked to clinical outcomes, and the impact of choice and length of antithrombotic therapy have not been specifically investigated. Here, we review different procedure-related factors and patient characteristics that might increase the risk of re-thrombosis and the utility of antithrombotic treatment options currently available.
Keywords: Venous stent, anticoagulation, iliofemoral vein thrombosis, direct oral anticoagulants, postthrombotic syndrome, aetiology.
Current Pharmaceutical Design
Title:Anticoagulation after Iliofemoral Vein Stenting - Old Versus New
Volume: 24 Issue: 38
Author(s): Anja B. Drebes* Neil H. Davies
Affiliation:
- KD Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London,United Kingdom
Keywords: Venous stent, anticoagulation, iliofemoral vein thrombosis, direct oral anticoagulants, postthrombotic syndrome, aetiology.
Abstract: In recent years, there has been an increasing interest in endovascular iliofemoral vein stenting to prevent/ alleviate symptoms related to proximal venous outflow obstruction. Maintaining long-term stent patency is one of the main challenges, and risk factors for the development of re-thrombosis are not well understood. Published data on the safety and efficacy of the procedure predominantly come from cohort studies mainly focusing on mechanical aspects relating to stent placement and flow. Aetiology of thrombus formation and thrombotic tendencies of patients due to underlying medical conditions are not captured well or linked to clinical outcomes, and the impact of choice and length of antithrombotic therapy have not been specifically investigated. Here, we review different procedure-related factors and patient characteristics that might increase the risk of re-thrombosis and the utility of antithrombotic treatment options currently available.
Export Options
About this article
Cite this article as:
Drebes B. Anja *, Davies H. Neil, Anticoagulation after Iliofemoral Vein Stenting - Old Versus New, Current Pharmaceutical Design 2018; 24 (38) . https://dx.doi.org/10.2174/1381612825666181226151114
DOI https://dx.doi.org/10.2174/1381612825666181226151114 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Dengue: Recent Advances in Biology and Current Status of Translational Research
Current Molecular Medicine Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer
Current Immunology Reviews (Discontinued) Dendritic Cell Immunotherapy for Acute Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Current Medicinal Chemistry Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Immunotherapy and Cancer Vaccines in the Management of Breast Cancer
Current Pharmaceutical Design Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders
Current Pharmaceutical Design Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Is the Prevalence of Estimated Pelvic Congestion Higher than Examined? A Retrospective Study of Consecutive Abdominopelvic Computed Tomography Analyses
Current Medical Imaging Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment
Current Pharmaceutical Design Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Immunotherapy for Malignant Melanoma Robert
Current Stem Cell Research & Therapy The Importance of Steroidomics in the Study of Neurodegenerative Disease and Ageing
Combinatorial Chemistry & High Throughput Screening Inhibition of RNA Virus Infections with Peptide-Conjugated Morpholino Oligomers
Current Pharmaceutical Design Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Experimental Onco-Immunology Revisited
Current Cancer Therapy Reviews Current Status of Pharmacological Thrombolytic Therapy and Mechanical Thrombectomy for the Treatment of Acute Deep Venous Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry